Genvax

Genvax is a biotechnology startup based in Ames, Iowa, founded in 2021. The company's mission revolves around accelerating breakthrough solutions in the animal health industry. Genvax aims to develop next-generation RNA + nanoparticle vaccines for animal health, leveraging the expertise of its dynamic team of experienced scientists and entrepreneurs. Having a notable track record, co-founders Joel Harris and Dr. Hank Harris previously established and successfully sold Harrisvaccines to Merck Animal Health in 2015. Their recent Seed Round investment of $6.50 million on 10th August 2022 was supported by key investors including Rural Vitality Funds, Ag Startup Engine, Johnsonville Ventures, United Health Foundation, and Summit Agricultural Group. Genvax's vision emphasizes the rapid response to global demands, aiming to commercialize tools for livestock producers and veterinarians that are unparalleled in the market. The company seeks to cultivate new ideas to develop novel solutions and create a long-lasting impact on animal health worldwide. This demonstrates their commitment to creating a significant impact in the industry as they accelerate breakthrough solutions for the betterment of animal health.